Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "Subutex 8 mg" (116)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
What is an ATC-Code?
ATC-Overview
(Codice) 102 products
WHO-DDD
Page 1 of 2:
1
2
>>
L
IP
Azacitidin Stada 150 mg
304.64
366.50
10 %
Powder for injection suspension: Azacitidinum 150 mg
Spirig HealthCare AG
A / SL / SG
FB
G
IP
CI
CM
Gabapentin Viatris 300 mg
50
16.59
35.50
10 %
Capsules: Gabapentinum 300 mg
Viatris Pharma GmbH
B / SL / SG
FB
G
IP
CI
CM
Gabapentin Viatris 300 mg
100
33.16
54.50
10 %
Capsules: Gabapentinum 300 mg
Viatris Pharma GmbH
B / SL / SG
FB
G
IP
CI
Velariq 1 mg/ml
12 x 10 ml
PR
PR
k.A.
Salmon Pharma GmbH
B
FB
G
IP
CI
Velariq 1 mg/ml
96 x 10 ml
PR
PR
k.A.
Salmon Pharma GmbH
B
FB
G
IP
Ph
Ginkgo-Mepha 240 mg
30
PR
PR
k.A.
Coated tablets: Ginkgonis Extractum Siccum Raffinatum et Quantificatum (Ginkgo Biloba l., Folium) 240 mg
Mepha Pharma AG
B
FB
G
IP
Ph
Ginkgo-Mepha 240 mg
60
PR
PR
k.A.
Coated tablets: Ginkgonis Extractum Siccum Raffinatum et Quantificatum (Ginkgo Biloba l., Folium) 240 mg
Mepha Pharma AG
B
FB
G
IP
Ph
Ginkgo-Mepha 240 mg
90
PR
PR
k.A.
Coated tablets: Ginkgonis Extractum Siccum Raffinatum et Quantificatum (Ginkgo Biloba l., Folium) 240 mg
Mepha Pharma AG
B
FB
G
IP
CI
Sonotryl
10
PR
PR
k.A.
Coated tablets: Ibuprofenum 200 mg
VERFORA SA
D
FB
G
IP
CI
Sonotryl
20
PR
PR
k.A.
Coated tablets: Ibuprofenum 200 mg
VERFORA SA
D
FB
G
IP
Xenpozyme 4 mg
PR
PR
k.A.
poudre pour solution à diluer pour perfusion: Olipudasum Alfa 4 mg
Sanofi-Aventis
(Suisse) SA
A
FB
G
IP
Xenpozyme 4 mg
10
PR
PR
k.A.
poudre pour solution à diluer pour perfusion: Olipudasum Alfa 4 mg
Sanofi-Aventis
(Suisse) SA
A
FB
G
IP
Xenpozyme 20 mg
PR
PR
k.A.
poudre pour solution à diluer pour perfusion: Olipudasum Alfa 20 mg
Sanofi-Aventis
(Suisse) SA
A
FB
G
IP
Xenpozyme 20 mg
10
PR
PR
k.A.
poudre pour solution à diluer pour perfusion: Olipudasum Alfa 20 mg
Sanofi-Aventis
(Suisse) SA
A
FB
G
L
IP
CI
A
Subutex 0,4 mg
7 Tablet(s)
2.97
7.50
10 %
Sublingual tablets: Buprenorphinum
Indivior Schweiz AG
A+ / SL / SO
FB
G
L
IP
CI
A
Subutex 2 mg
28 Tablet(s)
25.23
45.40
10 %
Sublingual tablets: Buprenorphinum 2 mg
Indivior Schweiz AG
A+ / SL / SO
FB
G
L
IP
CI
A
Subutex 8 mg
28 Tablet(s)
90.60
120.55
10 %
Sublingual tablets: Buprenorphinum 8 mg
Indivior Schweiz AG
A+ / SL / SO
FB
G
IP
CI
Dilzem 90 mg retard
20 Tablet(s)
3.26
7.85
10 %
Delayed release tablets: Diltiazemi Hydrochloridum 90 mg
Pfizer AG
B / SL / SO
FB
G
IP
CI
Dilzem 90 mg retard
100 Tablet(s)
14.05
28.45
10 %
Delayed release tablets: Diltiazemi Hydrochloridum 90 mg
Pfizer AG
B / SL / SO
FB
G
L
IP
CI
Januvia 100 mg
-
T
28 Tablet(s)
26.82
47.25
20 %
Coated tablets: 2 Active Agents
MSD Merck Sharp &
Dohme AG
B / SL / SO
FB
G
L
IP
CI
Januvia 100 mg
-
T
98 Tablet(s)
93.85
124.25
20 %
Coated tablets: 2 Active Agents
MSD Merck Sharp &
Dohme AG
B / SL / SO
FB
G
L
IP
CI
Januvia 25 mg
-
T
28 Tablet(s)
26.82
47.25
20 %
Coated tablets: Sitagliptinum 25 mg
MSD Merck Sharp &
Dohme AG
B / SL / SO
FB
G
L
IP
CI
Januvia 25 mg
-
T
98 Tablet(s)
93.85
124.25
20 %
Coated tablets: Sitagliptinum 25 mg
MSD Merck Sharp &
Dohme AG
B / SL / SO
FB
G
L
IP
CI
Januvia 50 mg
-
T
28 Tablet(s)
26.82
47.25
20 %
Coated tablets: Sitagliptinum 50 mg
MSD Merck Sharp &
Dohme AG
B / SL / SO
FB
G
L
IP
CI
Januvia 50 mg
-
T
98 Tablet(s)
93.85
124.25
20 %
Coated tablets: Sitagliptinum 50 mg
MSD Merck Sharp &
Dohme AG
B / SL / SO
FB
G
IP
CI
Fentalis 12 μg/h
5
9.47
19.10
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Fentalis 25 μg/h
5
15.79
34.55
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Fentalis 37.5 μg/h
5
28.40
49.05
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Fentalis 50 μg/h
5
31.27
52.35
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Fentalis 75 μg/h
5
45.89
69.15
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Fentalis 100 μg/h
5
58.80
84.00
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
CI
Fentalis 12 μg/h
10
17.19
36.15
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Fentalis 25 μg/h
10
27.66
48.20
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Fentalis 37.5 μg/h
10
51.56
75.65
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Fentalis 50 μg/h
10
56.76
81.65
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Fentalis 75 μg/h
10
80.57
109.00
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Fentalis 100 μg/h
10
103.47
135.30
10 %
Sandoz
Pharmaceuticals AG
A+ / SL / SG
FB
G
IP
Cisplatin Sandoz 50
mg/100 ml
Durchstechflasche(n)
58.90
84.10
10 %
Concentrate for infusion: Cisplatinum 50mg / 100ml
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
Azacitidin Ideogen 100 mg
189.00
233.60
10 %
Powder for injection suspension: Azacitidinum 100 mg
Ideogen AG
A / SL / SG
FB
G
L
IP
Ceftriaxon Labatec 2 g
i.v.
2 g
9.90
19.60
10 %
Dry substance: Ceftriaxonum 2000 mg
Labatec Pharma SA
A / SL / SG
FB
G
L
IP
Ceftriaxon Labatec 2 g
i.v.
10 x 2 g
84.15
113.10
10 %
Dry substance: Ceftriaxonum 2000 mg
Labatec Pharma SA
A / SL / SG
FB
G
IP
CI
Anastrozol Sandoz
30 Tablet(s)
55.42
80.10
10 %
Coated tablets: Anastrozolum 1 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
IP
CI
Anastrozol Sandoz
100 Tablet(s)
182.48
226.10
10 %
Coated tablets: Anastrozolum 1 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
L
IP
Ceftriaxon Labatec 1 g
i.v./i.m.
1 g
6.15
15.30
10 %
poudre pour solution injectable: Ceftriaxonum 1000 mg
Labatec Pharma SA
A / SL / SG
FB
G
L
IP
Ceftriaxon Labatec 1 g
i.v./i.m.
10 x 1 g
52.25
76.45
10 %
poudre pour solution injectable: Ceftriaxonum 1000 mg
Labatec Pharma SA
A / SL / SG
FB
G
IP
Lasix 20 mg/2 mL
5 ampoule(s)
1.61
5.95
10 %
Injection solution: Furosemidum 20mg / 2ml
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
L
IP
VEYVONDI 650 IE
650
532.84
587.75
10 %
Lyophilisate and solvent: Vonicogum Alfa 650 UI
Takeda Pharma AG
B / SL
FB
G
L
IP
VEYVONDI 1300 IE
1300
1065.68
1134.45
10 %
Lyophilisate and solvent: Vonicogum Alfa 1300 UI
Takeda Pharma AG
B / SL
FB
G
L
IP
CI
Renvela 2.4 g
60 Sachet(s)
141.67
179.20
10 %
Soluble Powder: Sevelameri Carbonas 2400 mg
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
L
IP
Rixathon 500 mg/50 ml
1051.32
1215.70
10 %
Concentrate for infusion: Rituximabum 500mg / 50ml
Sandoz
Pharmaceuticals AG
A / SL
FB
G
L
IP
Rixathon 100 mg/10 ml
2
421.97
501.30
10 %
Concentrate for infusion: Rituximabum 100mg / 10ml
Sandoz
Pharmaceuticals AG
A / SL
FB
G
L
IP
Vegzelma 100 mg/4 ml
257.57
312.40
10 %
Concentrate for infusion: Bevacizumabum 100mg / 4ml
iQone Healthcare
Switzerland SA
A / SL
FB
G
L
IP
Vegzelma 400 mg/16 ml
962.84
1118.60
10 %
Concentrate for infusion: Bevacizumabum 400mg / 16ml
iQone Healthcare
Switzerland SA
A / SL
FB
G
IP
CI
Dilzem 120 mg retard
30 Tablet(s)
5.75
14.80
10 %
Delayed release tablets: Diltiazemi Hydrochloridum 120 mg
Pfizer AG
B / SL
FB
G
IP
CI
Dilzem 120 mg retard
100 Tablet(s)
16.05
34.85
10 %
Delayed release tablets: Diltiazemi Hydrochloridum 120 mg
Pfizer AG
B / SL
FB
G
IP
CI
Aldara 5 %
12 Sachet(s)
65.66
91.85
10 %
Cream: Imiquimodum 50 mg/g
Viatris Pharma GmbH
A / SL
FB
G
L
IP
CI
Ph
Ginkgo-Mepha 80 mg
60 Tablet(s)
21.02
40.55
10 %
Coated tablets: Ginkgonis Extractum Siccum Raffinatum et Quantificatum (Ginkgo Biloba l., Folium) 80 mg
Mepha Pharma AG
B / SL
FB
G
L
IP
CI
Ph
Ginkgo-Mepha 80 mg
120 Tablet(s)
37.00
58.95
10 %
Coated tablets: Ginkgonis Extractum Siccum Raffinatum et Quantificatum (Ginkgo Biloba l., Folium) 80 mg
Mepha Pharma AG
B / SL
FB
G
L
IP
CI
Steglujan 5 mg /100 mg
28
58.33
83.45
10 %
Coated tablets: 2 Active Agents
MSD Merck Sharp &
Dohme AG
B / SL
FB
G
L
IP
CI
Steglujan 5 mg /100 mg
98
204.16
251.00
10 %
Coated tablets: 2 Active Agents
MSD Merck Sharp &
Dohme AG
B / SL
FB
G
L
SIP
IP
CI
Xarelto 10 mg
-
T
10 Tablet(s)
22.39
42.15
10 %
Coated tablets: Rivaroxabanum 10 mg
Bayer (Schweiz) AG
B / SL
FB
G
L
SIP
IP
CI
Xarelto 10 mg
-
T
30 Tablet(s)
67.17
93.60
10 %
Coated tablets: Rivaroxabanum 10 mg
Bayer (Schweiz) AG
B / SL
FB
G
L
SIP
IP
CI
Xarelto 10 mg
-
T
98
230.43
281.20
10 %
Coated tablets: Rivaroxabanum 10 mg
Bayer (Schweiz) AG
B / SL
FB
G
SIP
IP
CI
Xarelto 15 mg
14 Tablet(s)
32.17
53.40
10 %
Coated tablets: Rivaroxabanum 15 mg
Bayer (Schweiz) AG
B / SL
FB
G
SIP
IP
CI
Xarelto 15 mg
28 Tablet(s)
62.83
88.60
10 %
Coated tablets: Rivaroxabanum 15 mg
Bayer (Schweiz) AG
B / SL
FB
G
SIP
IP
CI
Xarelto 15 mg
98 Tablet(s)
230.43
281.20
10 %
Coated tablets: Rivaroxabanum 15 mg
Bayer (Schweiz) AG
B / SL
FB
G
SIP
IP
CI
Xarelto 20 mg
14 Tablet(s)
32.37
53.60
10 %
Coated tablets: Rivaroxabanum 20 mg
Bayer (Schweiz) AG
B / SL
FB
G
SIP
IP
CI
Xarelto 20 mg
28 Tablet(s)
62.83
88.60
10 %
Coated tablets: Rivaroxabanum 20 mg
Bayer (Schweiz) AG
B / SL
FB
G
SIP
IP
CI
Xarelto 20 mg
98 Tablet(s)
230.43
281.20
10 %
Coated tablets: Rivaroxabanum 20 mg
Bayer (Schweiz) AG
B / SL
FB
G
L
IP
CI
PP
Elvanse 20 mg
30
80.84
109.30
10 %
Capsules: Lisdexamfetamini Dimesilas 20 mg
Takeda Pharma AG
● 
A+ / SL
FB
G
L
IP
CI
PP
Elvanse 30 mg
30 Capsule(s)
86.89
116.25
10 %
Capsules: Lisdexamfetamini Dimesilas 30 mg
Takeda Pharma AG
A+ / SL
FB
G
L
IP
CI
PP
Elvanse 40 mg
30
93.29
123.60
10 %
Capsules: Lisdexamfetamini Dimesilas 40 mg
Takeda Pharma AG
A+ / SL
FB
G
L
IP
CI
PP
Elvanse 50 mg
30 Capsule(s)
99.69
130.95
10 %
Capsules: Lisdexamfetamini Dimesilas 50 mg
Takeda Pharma AG
A+ / SL
FB
G
L
IP
CI
PP
Elvanse 60 mg
30
107.18
139.60
10 %
Capsules: Lisdexamfetamini Dimesilas 60 mg
Takeda Pharma AG
A+ / SL
FB
G
L
IP
CI
PP
Elvanse 70 mg
30 Capsule(s)
114.64
148.15
10 %
Capsules: Lisdexamfetamini Dimesilas 70 mg
Takeda Pharma AG
A+ / SL
FB
G
L
IP
PP
Herceptin subkutan
600mg/5ml
1484.04
1690.75
10 %
Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
L
IP
Ogivri 150 mg
456.84
541.40
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg
Medius AG
A / SL
FB
G
IP
CI
V/S
Comirnaty®
Original/Omicron BA.1
15/15 µg pro Dosis
gebrauchsfertige
Injektionsdispersion für
Personen ab 18 Jahren
10
PR
PR
k.A.
2 Active Agents
Pfizer AG
B
FB
G
IP
CI
V/S
Comirnaty®
Original/Omicron BA.1
15/15 µg pro Dosis
gebrauchsfertige
Injektionsdispersion für
Personen ab 18 Jahren
195
PR
PR
k.A.
2 Active Agents
Pfizer AG
B
FB
G
IP
CI
Bilaxten 6 mg / ml
5 ml
PR
PR
k.A.
Eye drops: Bilastinum 6 mg/ml
A. Menarini GmbH
B
FB
G
IP
CI
A
Subutex 0,4 mg
28 Tablet(s)
PR
PR
k.A.
Sublingual tablets: Buprenorphinum
Indivior Schweiz AG
A+
FB
G
IP
CI
A
Subutex 2 mg
7 Tablet(s)
7.04
16.30
k.A.
Sublingual tablets: Buprenorphinum 2 mg
Indivior Schweiz AG
A+
FB
G
IP
CI
A
Subutex 8 mg
7 Tablet(s)
24.58
44.60
k.A.
Sublingual tablets: Buprenorphinum 8 mg
Indivior Schweiz AG
A+
FB
G
IP
Renvela 0.8 g
90
PR
PR
k.A.
Soluble Powder: Sevelameri Carbonas 800 mg
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
Rixathon 500 mg/50 ml
2
PR
PR
k.A.
Concentrate for infusion: Rituximabum 500mg / 50ml
Sandoz
Pharmaceuticals AG
A
FB
G
IP
Rixathon 100 mg/10 ml
3
PR
PR
k.A.
Concentrate for infusion: Rituximabum 100mg / 10ml
Sandoz
Pharmaceuticals AG
A
FB
G
IP
Xevudy
PR
PR
k.A.
Concentrate for infusion: Sotrovimabum 500mg / 8ml
GlaxoSmithKline AG
A
FB
G
SIP
IP
CI
Xarelto 10 mg
-
T
10 1 Tablet(s)
PR
PR
k.A.
Coated tablets: Rivaroxabanum 10 mg
Bayer (Schweiz) AG
B
FB
G
SIP
IP
CI
Xarelto 10 mg
-
T
30 x 1
PR
PR
k.A.
Coated tablets: Rivaroxabanum 10 mg
Bayer (Schweiz) AG
B
FB
G
SIP
IP
CI
Xarelto 10 mg
-
T
100
PR
PR
k.A.
Coated tablets: Rivaroxabanum 10 mg
Bayer (Schweiz) AG
B
FB
G
SIP
IP
CI
Xarelto 15 mg
10 1 Tablet(s)
PR
PR
k.A.
Coated tablets: Rivaroxabanum 15 mg
Bayer (Schweiz) AG
B
FB
G
SIP
IP
CI
Xarelto 15 mg
30 x 1
PR
PR
k.A.
Coated tablets: Rivaroxabanum 15 mg
Bayer (Schweiz) AG
B
FB
G
SIP
IP
CI
Xarelto 15 mg
100
PR
PR
k.A.
Coated tablets: Rivaroxabanum 15 mg
Bayer (Schweiz) AG
B
FB
G
SIP
IP
CI
Xarelto 20 mg
10 1 Tablet(s)
PR
PR
k.A.
Coated tablets: Rivaroxabanum 20 mg
Bayer (Schweiz) AG
B
FB
G
SIP
IP
CI
Xarelto 20 mg
30 x 1
PR
PR
k.A.
Coated tablets: Rivaroxabanum 20 mg
Bayer (Schweiz) AG
B
FB
G
SIP
IP
CI
Xarelto 20 mg
100
PR
PR
k.A.
Coated tablets: Rivaroxabanum 20 mg
Bayer (Schweiz) AG
B
FB
G
IP
CI
Dafalgan Grippal
12
PR
PR
k.A.
Granulat zur Herstellung einer Lösung zum Einnehmen: 3 Active Agents
UPSA Switzerland AG
D
FB
G
IP
CI
V/S
Comirnaty
195
PR
PR
k.A.
Konzentrat zur Herstellung einer Injektionsdispersion: Tozinameranum 225 µg
Pfizer AG
B
FB
G
IP
Elmex fluid
50 ml
PR
PR
k.A.
Lösung zur Anwendung in der Mundhöhle: Fluoridum 10 mg/g
Gaba Schweiz AG
B
FB
G
IP
Mylotarg 5 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg
Pfizer AG
A
FB
G
IP
Ceftriaxon Labatec 250 mg
i.m.
10 x 250 mg
PR
PR
k.A.
poudre pour solution injectable: Ceftriaxonum 250 mg
Labatec Pharma SA
A
FB
G
IP
Ceftriaxon Labatec 500 mg
i.v.
10 x 500 mg
PR
PR
k.A.
poudre pour solution injectable: Ceftriaxonum 500 mg
Labatec Pharma SA
A
FB
G
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2024
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home